High PSALow volume diseaseRarely, patients with prostate cancer (PC) present with Prostate-Specific Antigen (PSA) scores >20ng/mL but otherwise very low-risk disease. Oncologists debate whether malignancies in these patients behave more comparably to low-risk or high-risk disease. Our objective ...
Objective High-dose-rate (HDR) brachytherapy boost represents a method to dose escalate in high-risk prostate cancer; the purpose of this analysis is to report long-term outcomes for a group of high-risk patients with Gleason 8 through 10 prostate cancer treated with HDR brachytherapy boost from...
PSA and PSA velocity (PSAV, rate of PSA change over time) are biomarkers for diagnosis and prognosis of prostate cancer. Men who are at high risk for prostate cancer also have associated comorbidities for which they are taking NSAIDs and statins for long periods; therefore, it is important ...
Cancer immunotherapies such as bispecific T-cell engagers have seen limited adoption in prostate cancer (PC), possibly due to differing levels of cancer receptor expression and effector T-cell infiltration between patients and inherent defects in T-cell engager design. Methods CD8+ T-cell infiltration...
Metastatic prostate cancer is a highly heterogeneous and dynamic disease and practicable tools for patient stratification and resistance monitoring are urgently needed. Liquid biopsy analysis of circulating tumor cells (CTCs) and circulating tumor DNA are promising, however, comprehensive testing is essential...
a. The association between histological invasion status and recurrence-free survival in our cohort (Kaplan-Meier analysis, log-rank test, n numbers shown represent patients). b. Distributions of age (n = 125) and plasma PSA (n = 117) levels of patients in our cohort. For the box...
Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic castration-resistant prostate cancer (nmCRPC), reports theJournal of Urology. ...
Objectives: To determine the incidence and magnitude of the rapid increase in the serum PSA (riPSA) level after high-intensity focused ultrasound (HIFU) therapy for prostate cancer, and its correlation with clinical factors. Methods: A total of 176 patients with localized prostate cancer underwent...
(2012) Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis. ... C Li,L Xu,X Lin,... - 《Medicine》 被引量: 0发表: 2021年 Statin Use and Fatal Prostate Cancer: A Matched Case-Control Study BACKGR...
Data presented at the ESMO Congress 2022 highlighted advances across treatment modalities, including landmark data for trials in melanoma, breast cancer, and lung cancer, as well as early data that made headlines in a subgroup of patients with colon canc